Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01604252
Other study ID # ML28296
Secondary ID
Status Terminated
Phase N/A
First received May 21, 2012
Last updated July 25, 2017
Start date June 20, 2012
Est. completion date April 28, 2017

Study information

Verified date June 2017
Source Genentech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome. The total study duration is anticipated to be a maximum of 8 years, including 3 years for patient recruitment and 5 years follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 503
Est. completion date April 28, 2017
Est. primary completion date April 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Patients with basal cell carcinoma (BCC) who meet either of the following definitions:

- Patients who were determined with advanced disease (aBCC) within 90 days prior to study enrollment, have not been diagnosed with basal cell carcinoma nevus syndrome (BCCNS) and have not been treated with an investigational or approved hedgehog pathway inhibitor

- Patients with aBCC who have not been diagnosed with BCCNS and who were previously treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)

- Patients with BCCNS who either have aBCC or multiple BCCs of any stage as defined by protocol (may include patients previously enrolled in Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP))

Exclusion Criteria:

- Participation in a clinical trial within 90 days prior to study enrollment that has either involved treatment of aBCC or involved treatment with an investigational or approved hedgehog pathway inhibitor, except for patients treated with vismodegib as part of Genentech study SHH4476g, SHH4437g, or SHH4811g (EAP)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Puerto Rico Alma M Cruz MD Carolina
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Georgia Skin Cancer and Aesthetic Dermatology Athens Georgia
United States Emory Univ Winship Cancer Inst Atlanta Georgia
United States University of Colorado; Anschutz Cancer Pavilion Aurora Colorado
United States Beverly Hospital, A Member of Lahey Health Beverly Massachusetts
United States Moy-Fincher-Chipps Facial Plastics and Dermatology Beverly Hills California
United States Manish J. Gharia, MD Brookfield Wisconsin
United States Cooper University Hospital Camden New Jersey
United States Laser & Skin Surgery Center of Indiana Carmel Indiana
United States Shideler Clinical Research Center Carmel Indiana
United States University of North Carolina At Chapel Hill Chapel Hill North Carolina
United States Dermatology and Laser Center of Charleston PA Charleston South Carolina
United States Laser and Dermatologic Surgery Center Chesterfield Missouri
United States Northwestern University Chicago Illinois
United States Cleveland Clinic Foundation Cleveland Ohio
United States Ohio State University; Comp Can Ctr Columbus Ohio
United States Dermatology Associates and Research Coral Gables Florida
United States MLF Knuckles, MD, PSC Corbin Kentucky
United States Duke University Medical Center Durham North Carolina
United States NOVA Southeastern University Fort Lauderdale Florida
United States Hackensack University Medical Center Hackensack New Jersey
United States Associated Dermatology and Skin Cancer Clinic of Helena, PC Helena Montana
United States Bettencourt Skin Center Henderson Nevada
United States Hollywood Dermatology and Cosmetic Specialists Hollywood Florida
United States DermSurgery Associates, PA Houston Texas
United States Huntington Internal Medicine Group Huntington West Virginia
United States University of California Irvine Irvine California
United States University of Mississippi Medical Center; Division of Dermatology Jackson Mississippi
United States Mayo Clinic-Jacksonville Jacksonville Florida
United States Faulkner Hospital Jamaica Plain Massachusetts
United States Scripps Clinic; Hematology & Oncology La Jolla California
United States University of California San Diego La Jolla California
United States South Texas Research Alliance LLC Laredo Texas
United States Linda Woodson Dermatology, A Professional Corporation Las Vegas Nevada
United States Strimling Dermatology, Laser and Vein Institute Las Vegas Nevada
United States Woodson Dermatology Las Vegas Nevada
United States Fairmont Dermatology Medical Associates, Inc. Lodi California
United States Loma Linda University Medical Center Loma Linda California
United States Dermatology Research Associate Los Angeles California
United States Derm Research, LLC Louisville Kentucky
United States Dermatologic Surgery Specialists, Inc Macon Georgia
United States Northwest Georgia Dermatology and Skin Cancer Specialists Marietta Georgia
United States University of Miami Miami Florida
United States University of Minnesota. Minneapolis Minnesota
United States Atlantic Health System Morristown New Jersey
United States The Sarah Cannon Research Inst Nashville Tennessee
United States Columbia University Medical Center New York New York
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Mount Sinai Medical Center New York New York
United States Newport Dermatology and Laser Associates Newport Beach California
United States University of Oklahoma Health Sciences Cente; Department of Dermatology Oklahoma City Oklahoma
United States Advanced Derm & Cosmetic Surg Ormond Beach Florida
United States Stanford University Palo Alto California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Belleair Research Center Pinellas Park Florida
United States Indiana Clinical Trial Center Plainfield Indiana
United States Skin and Cancer Associates and the Center for Cosmetic Enhancement Plantation Florida
United States Skin Cancer and Dermatology Institute Reno Nevada
United States University of Rochester Rochester New York
United States Saint Louis University School of Medicine; Department of Dermatology Saint Louis Missouri
United States Spencer Derma & Skin Surg Ctr Saint Petersburg Florida
United States Skin Surgery Med Group, Inc San Diego California
United States University Clinical Trials San Diego California
United States Clinical Research Specialists, Inc. Santa Monica California
United States California Pacific Medical Center Research Institute Santa Rosa California
United States Mayo Clinic Scottsdale Arizona
United States Dermatology Associates PLLC Seattle Washington
United States Florida Research Specialists Seminole Florida
United States Long Island Skin Cancer and Dermatologic Surgery Smithtown New York
United States Gwinnett Clinical Research Center Snellville Georgia
United States Southern IL Univ School of Med Springfield Illinois
United States H. Lee Moffitt Cancer Center and Research Inst. Tampa Florida
United States University of South Florida Tampa Florida
United States Pacific Dermatology Institute Temecula California
United States Arizona Cancer Center Tucson Arizona
United States Advanced Derm & Cosmetic Care Valencia California
United States Dermatology Group, P.C. Verona New Jersey
United States South Valley Dermatology Center West Jordan Utah
United States Kenneth R. Beer, M.D., PA West Palm Beach Florida
United States The Skin Surgery Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate approximately 5 years
Primary Duration of response approximately 5 years
Primary Recurrence rate approximately 5 years
Primary Progression-free survival approximately 5 years
Primary Overall survival approximately 5 years
Primary Safety: Incidence of adverse events approximately 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT05608902 - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed NCT05077033 - Intratumoral phIL12 GET Phase 1
Active, not recruiting NCT04928222 - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) Phase 1/Phase 2
Recruiting NCT04929535 - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment Phase 2
Completed NCT02662244 - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma N/A
Completed NCT00959647 - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Phase 2
Completed NCT00793169 - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed NCT00586040 - Photochemical Tissue Bonding Phase 2
Completed NCT00473343 - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma Phase 3
Active, not recruiting NCT06024629 - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting NCT05324202 - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management N/A
Withdrawn NCT04099446 - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT01201915 - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma Phase 2
Completed NCT01208831 - An East Asian Study of LDE225 Phase 1
Completed NCT01260987 - Fractional CO2 Laser Assisted Photodynamic Therapy Phase 2/Phase 3
Completed NCT01014819 - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions N/A
Completed NCT00472043 - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Phase 3